Furosemide Use in Acute Kidney Injury

General Recommendations for Furosemide in AKI

The Kidney International guidelines recommend that diuretics, including furosemide, should not be used to prevent acute kidney injury (AKI) (level 1B recommendation) 1, 2, 3
Furosemide should not be used to treat AKI except in the management of volume overload (level 2C recommendation) 1, 2, 4
Randomized controlled trials and meta-analyses demonstrate that furosemide does not prevent AKI and may lead to increased mortality 1
In cases where volume overload complicates AKI, diuretics may actually improve outcomes 1, 2

Furosemide should only be used in hemodynamically stable patients with AKI who have volume overload 1, 2
In patients with acute pulmonary edema and AKI, furosemide may be appropriate for managing volume overload 5

Furosemide administration is associated with worsening renal function, with studies showing a 60 mg greater total dose of furosemide the day before in patients who developed worsening renal function 5
Regular monitoring is essential during IV diuretic therapy, including hourly urine output monitoring 6
Daily renal function assessment is recommended during IV diuretic therapy 6
Electrolyte monitoring every 12-24 hours is recommended during IV diuretic therapy 6

For heart failure patients with AKI, consider starting with a lower dose of 20 mg IV furosemide for patients with new-onset heart failure or those not on chronic diuretics 6
For patients already on chronic diuretic therapy, the initial IV dose should be at least equivalent to their home oral dose 6
Consider reducing the dose by 25-50% if AKI is significant 6
Avoid combining furosemide with other nephrotoxic medications, as each nephrotoxin administration presents a 53% greater odds of developing AKI 7

Using furosemide in hemodynamically unstable patients with AKI can precipitate volume depletion, hypotension, and further renal hypoperfusion 1, 2
The potential benefit of furosemide in non-volume overloaded AKI patients is outweighed by risks 1, 2

The International Club of Ascites recommends reviewing all medications and withdrawing diuretics as a first-line management step for patients with cirrhosis and AKI stage 1, and withdrawing furosemide immediately in patients presenting with new AKI 8

The American College of Physicians and other guideline societies imply that furosemide should not be used to convert oliguric to non-oliguric AKI, as this practice lacks evidence of benefit 9
Avoid combining furosemide with other nephrotoxic medications, as each nephrotoxin increases AKI odds by 53%, according to the National Kidney Foundation and other organizations 10

For patients with cirrhosis and ascites and AKI, the management algorithm requires a stepwise approach, including withdrawing diuretics immediately, plasma volume expansion with albumin, and only restarting diuretics if volume overload persists after treating underlying causes, as recommended by the International Ascites Club 8